Logo image of CRVO

CERVOMED INC (CRVO) Stock Fundamental Analysis

NASDAQ:CRVO - Nasdaq - US15713L1098 - Common Stock - Currency: USD

8.43  +1.02 (+13.77%)

After market: 8.4 -0.03 (-0.36%)

Fundamental Rating

3

Taking everything into account, CRVO scores 3 out of 10 in our fundamental rating. CRVO was compared to 556 industry peers in the Biotechnology industry. While CRVO has a great health rating, there are worries on its profitability. CRVO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRVO has reported negative net income.
CRVO had a negative operating cash flow in the past year.
In the past 5 years CRVO always reported negative net income.
CRVO had a negative operating cash flow in each of the past 5 years.
CRVO Yearly Net Income VS EBIT VS OCF VS FCFCRVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

CRVO has a Return On Assets (-48.40%) which is in line with its industry peers.
CRVO has a Return On Equity of -53.92%. This is in the better half of the industry: CRVO outperforms 63.13% of its industry peers.
Industry RankSector Rank
ROA -48.4%
ROE -53.92%
ROIC N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
CRVO Yearly ROA, ROE, ROICCRVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K

1.3 Margins

CRVO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVO Yearly Profit, Operating, Gross MarginsCRVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for CRVO has been increased compared to 1 year ago.
Compared to 5 years ago, CRVO has more shares outstanding
There is no outstanding debt for CRVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRVO Yearly Shares OutstandingCRVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
CRVO Yearly Total Debt VS Total AssetsCRVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 6.59 indicates that CRVO is not in any danger for bankruptcy at the moment.
CRVO's Altman-Z score of 6.59 is amongst the best of the industry. CRVO outperforms 80.58% of its industry peers.
There is no outstanding debt for CRVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.59
ROIC/WACCN/A
WACCN/A
CRVO Yearly LT Debt VS Equity VS FCFCRVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 9.78 indicates that CRVO has no problem at all paying its short term obligations.
CRVO has a better Current ratio (9.78) than 78.06% of its industry peers.
A Quick Ratio of 9.78 indicates that CRVO has no problem at all paying its short term obligations.
CRVO's Quick ratio of 9.78 is fine compared to the rest of the industry. CRVO outperforms 78.06% of its industry peers.
Industry RankSector Rank
Current Ratio 9.78
Quick Ratio 9.78
CRVO Yearly Current Assets VS Current LiabilitesCRVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

2

3. Growth

3.1 Past

CRVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -632.78%.
Looking at the last year, CRVO shows a decrease in Revenue. The Revenue has decreased by -2.00% in the last year.
EPS 1Y (TTM)-632.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.59%
Revenue 1Y (TTM)-2%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.32%

3.2 Future

Based on estimates for the next years, CRVO will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.38% on average per year.
The Revenue is expected to grow by 13.43% on average over the next years. This is quite good.
EPS Next Y-1.7%
EPS Next 2Y5.29%
EPS Next 3Y3.56%
EPS Next 5Y9.38%
Revenue Next Year-33.97%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y13.43%

3.3 Evolution

CRVO Yearly Revenue VS EstimatesCRVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2028 2029 2030 2031 2032 200M 400M 600M 800M
CRVO Yearly EPS VS EstimatesCRVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRVO. In the last year negative earnings were reported.
Also next year CRVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVO Price Earnings VS Forward Price EarningsCRVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVO Per share dataCRVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.29%
EPS Next 3Y3.56%

More info and screens

0

5. Dividend

5.1 Amount

CRVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERVOMED INC

NASDAQ:CRVO (7/21/2025, 8:00:00 PM)

After market: 8.4 -0.03 (-0.36%)

8.43

+1.02 (+13.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-07 2025-08-07
Inst Owners26.31%
Inst Owner Change-0.04%
Ins Owners25.03%
Ins Owner Change0.23%
Market Cap73.34M
Analysts80
Price Target16.15 (91.58%)
Short Float %1.6%
Short Ratio0.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.89%
Min EPS beat(2)-24.49%
Max EPS beat(2)16.71%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-30.72%
Max EPS beat(4)16.71%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)15.25%
Min Revenue beat(2)9.17%
Max Revenue beat(2)21.32%
Revenue beat(4)3
Avg Revenue beat(4)9.77%
Min Revenue beat(4)-37.98%
Max Revenue beat(4)46.57%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.32%
EPS NQ rev (3m)6.8%
EPS NY rev (1m)0.49%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)11.55%
Revenue NQ rev (3m)0.97%
Revenue NY rev (1m)13.32%
Revenue NY rev (3m)5.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.88
P/FCF N/A
P/OCF N/A
P/B 2.12
P/tB 2.12
EV/EBITDA N/A
EPS(TTM)-2.18
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-2.18
FCFYN/A
OCF(TTM)-2.18
OCFYN/A
SpS1.07
BVpS3.98
TBVpS3.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.4%
ROE -53.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.78
Quick Ratio 9.78
Altman-Z 6.59
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-632.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.59%
EPS Next Y-1.7%
EPS Next 2Y5.29%
EPS Next 3Y3.56%
EPS Next 5Y9.38%
Revenue 1Y (TTM)-2%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.32%
Revenue Next Year-33.97%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y13.43%
EBIT growth 1Y-292.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.61%
EBIT Next 3Y-57.97%
EBIT Next 5Y-24.41%
FCF growth 1Y-24.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.95%
OCF growth 3YN/A
OCF growth 5YN/A